Congress bans exclusive health contracts—but carves out huge loopholes

What it does

This bill bans health insurance plans and providers from using exclusive or restrictive contracts that prevent plans from steering patients to lower-cost or higher-quality providers, or from negotiating lower rates with competing providers. It carves out exceptions for HMOs with exclusive physician groups and 'value-based' networks (like ACOs and centers of excellence), allowing those arrangements to remain exclusive. The bill applies to group health plans, individual insurance, and self-insured plans under three federal statutes (PHSA, ERISA, IRC).

Why we flagged it

The bill's core function is to restrict exclusive contracting in health insurance and provider networks to increase price competition and patient steering. It is framed as an antitrust/competition measure, though the exceptions are broad enough to potentially undermine its stated purpose.

What the text implies

• The exceptions for 'value-based network arrangements' are defined by reference to agency guidance/rulemaking, not statute. This delegates the scope of the ban to regulators and creates uncertainty about which exclusive arrangements remain legal—potentially allowing insurers and providers to repackage existing exclusive contracts as 'value-based' to evade the prohibition.
• The bill does not define 'directing or steering' or specify what incentives are permissible. Insurers may argue that tiering, prior authorization, or narrow networks constitute legitimate 'network design' rather than prohibited steering, creating litigation risk and regulatory ambiguity.

The full analysis lists 5 implications of this text.

Who stands to gain

smaller health systems and independent providers (may gain access to insurance networks); health insurance plans (may gain negotiating leverage and ability to steer to lower-cost providers); pharmacy benefit managers and third-party administrators (if they can offer competing networks)